The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Open accessAbstract
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of combination fibrate–statin therapy in such patients is consistent with current guidelines that recommend treatment for patients with hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy.25”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to practice guidelines in place at the time of patient enrollment in IMPROVE-IT, treatment of hypercholesterolemia was based on lowering LDL cholesterol to target levels, 20,21 which were set on the basis of a patient's risk of cardiovascular events.”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [20]
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Assiduous attention to abnormalities other than hyperglycemia that accompany type 2 diabetes, such as hypertension and dyslipidaemia, has been shown to improve microvascular and cardiovascular complications.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [21]
In the citing paper
“Nevertheless, measurement and treatment of blood lipids, blood pressure, and glucose levels have became the major emphases for cardiovascular risk reduction.”
From Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease (2008) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Self-citationOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,060
Ganse, E. H. V., Laforest, L., Alemao, E., Davies, G., Gutkin, S. W., & Yin, D. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x59139 · Cited by 87
Valenti, V., Hartaigh, B. Ó., Cho, I., Schulman‐Marcus, J., Gransar, H., Heo, R., Truong, Q. A., Shaw, L. J., Knapper, J. T., Kelkar, A. A., et al. (2016) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.115.003528 · Cited by 88
Jackson, E. A., Munir, K., SCHREIBER, T. L., Rubin, J. R., Cuff, R. F., Gallagher, K. A., Henke, P. K., Gurm, H. S., & Grossman, P. M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.036 · Cited by 88
Statin drug interactions and related adverse reactions
Bellosta, S., & Corsini, A. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.712959 · Cited by 111
Using Additional Information on Working Hours to Predict Coronary Heart Disease
Mika Kivimaki, B., Batty, G. D., Hamer, M., Ferrie, J. E., Vahtera, J., Virtanen, M., Marmot, M. G., Singh‐Manoux, A., & Shipley, M. J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-7-201104050-00003 · Cited by 87
Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
Kim, Y., Han, E., Lee, J. S., Lee, H. W., Kim, B. K., Kim, M. K., Kim, H. S., Park, J. Y., Kim, D. Y., Ahn, S. H., et al. (2021) · Gut and Liver · doi:10.5009/gnl210084 · Cited by 87
Tabatabaei‐Malazy, O., Moghaddam, S. S., Rezaei, N., Sheidaei, A., Hajipour, M. J., Mahmoudi, N., Mahmoudi, Z., Dilmaghani‐Marand, A., Rezaee, K., Sabooni, M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0241926 · Cited by 87
Studies on antidyslipidemic effects of Morinda citrifolia (Noni) fruit, leaves and root extracts
Mandukhail, S. R., Aziz, N., & Gilani, A. H. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-88 · Cited by 87
Boden, W. E., O’Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M. L., Dada, M. R., Casperson, P. R., Harris, C. L., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.08.015 · Cited by 87
Roh, E., Ko, S., Kwon, H., Kim, N. H., Kim, J. H., Kim, C. S., Song, K., Won, J. C., Kim, D. J., Choi, S. H., et al. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.6.433 · Cited by 90
Rashidi, A., Sehgal, A. R., Rahman, M., & Connor, A. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.07.060 · Cited by 87
Lipid Profile Components and Risk of Ischemic Stroke
Willey, J. Z., Xu, Q., Boden-Albala, B. M., Paik, M. C., Moon, Y. P., Sacco, R. L., & Elkind, M. S. V. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.210 · Cited by 87
Update on the NCEP ATP-III emerging cardiometabolic risk factors
Eckel, R. H., & Cornier, M. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-115 · Cited by 96
Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey
Park, J. E., Chiang, C., Munawar, M., Pham, G. K., Sukonthasarn, A., Aquino, A. R., Lin, K. K., & Chan, H. W. R. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826710397100 · Cited by 89
Kuznik, A., Mardekian, J., & Tarasenko, L. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-132 · Cited by 86
Toi, T., Taguchi, I., Yoneda, S., Kageyama, M., Kikuchi, A., Tokura, M., Kanaya, T., Abe, S., Matsuda, R., & Kaneko, N. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1051 · Cited by 86
Scholle, J. M., Baker, W. L., Talati, R., & Coleman, C. I. (2009) · Journal of the American College of Nutrition · doi:10.1080/07315724.2009.10719784 · Cited by 86
Should we measure routinely the LDL peak particle size?
Rizzo, M., & Berneis, K. K. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.02.035 · Cited by 86
Burke, J. F., Hayward, R. A., Nelson, J., & Kent, D. M. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000497 · Cited by 85
Nikpour, M., Urowitz, M. B., Ibañez, D., Harvey, P., & Gladman, D. D. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3473 · Cited by 86
Lipids and CVD management: towards a global consensus
Ballantyne, C. M., Arroll, B., & Shepherd, J. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi373 · Cited by 86
Pharmacogenomics of cholesterol-lowering therapy
Schmitz, G., & Langmann, T. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.07.012 · Cited by 86
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
Leiter, L. A., Betteridge, D. J., Farnier, M., Guyton, J. R., Lin, J., Shah, A., Johnson‐Levonas, A. O., & Brudi, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01383.x · Cited by 84
Pre-existing and machine learning-based models for cardiovascular risk prediction
Cho, S.-Y., Kim, S., Kang, S., Lee, K. J., Choi, D., Kang, S., Park, S. J., Kim, T., Yoon, C., Youn, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88257-w · Cited by 88
A Comprehensive Review of Metabolic Syndrome Affecting Erectile Dysfunction
Kaya‐Sezginer, E., Sikka, S. C., & Gür, S. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12828 · Cited by 84
Balancing Efficacy and Safety in Treatment with Antipsychotics
Correll, C. U. (2007) · CNS Spectrums · doi:10.1017/s1092852900026298 · Cited by 85
Hypercholesterolemia and inflammation in atherogenesis: Two sides of the same coin
Steinberg, D. H. (2005) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500081 · Cited by 88
Metabolic Syndrome, Inflammation, and Nonamnestic Mild Cognitive Impairment in Older Persons
Roberts, R. O., Geda, Y. E., Knopman, D. S., Cha, R. H., Boeve, B. F., Ivnik, R. J., Pankratz, V. S., Tangalos, E. G., & Petersen, R. C. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181a4485c · Cited by 85
Community Pharmacist–Provided Extended Diabetes Care
Doucette, W. R., Witry, M. J., Farris, K. B., & Mcdonough, R. P. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l605 · Cited by 85
Systematic Review of Guidelines on Imaging of Asymptomatic Coronary Artery Disease
Ferket, B. S., Genders, T. S. S., Colkesen, E. B., Visser, J. J., Spronk, S., Steyerberg, E. W., & Hunink, M. G. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.055 · Cited by 85
Therapeutic Plasma Exchange in Patients With Severe Hypertriglyceridemia: A Multicenter Study
Stefanutti, C., Giacomo, S. D., Vivenzio, A., Labbadia, G., Mazza, F., D’Alessandri, G., Russi, G., Silvestro, G. D., & Marson, P. (2009) · Artificial Organs · doi:10.1111/j.1525-1594.2009.00810.x · Cited by 85
Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease
Erickson, K. F., Japa, S., Owens, D. K., Chertow, G. M., Garber, A. M., & Goldhaber-Fiebert, J. D. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.034 · Cited by 74
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk
Brown, B. G., & Zhao, X.-Q. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.039 · Cited by 84
Improved diabetes control in the elderly delays global cognitive decline
Luchsinger, J. A., Palmas, W., Teresi, J. A., Silver, S., Kong, J., Eimicke, J. P., Weinstock, R. S., & Shea, S. (2011) · The journal of nutrition health & aging · doi:10.1007/s12603-011-0057-x · Cited by 87
Warnholtz, A., Wild, P. S., Ostad, M. A., Elsner, V., Stieber, F., Schinzel, R., Walter, U., Peetz, D., Lackner, K. J., Blankenberg, S., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.003 · Cited by 84
Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014
Rosenson, R. S., Farkouh, M. E., Mefford, M. T., Bittner, V., Brown, T. M., Taylor, B., Monda, K. L., Zhao, H., Dai, Y., & Muntner, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.585 · Cited by 84
Wen, J., Huang, Y., Lu, Y., & Yuan, H. (2019) · Hypertension Research · doi:10.1038/s41440-019-0251-5 · Cited by 88
Rong, S., Li, B., Chen, L., Sun, Y., Du, Y., Liu, B., Robinson, J. G., & Bao, W. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023690 · Cited by 88
Effectiveness of Pharmacist‐Administered Diabetes Mellitus Education and Management Services
Ragucci, K. R., Fermo, J. D., Wessell, A. M., & Chumney, E. C. G. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.12.1809 · Cited by 84
The endothelial cell in health and disease: its function, dysfunction, measurement and therapy
Schwartz, B. G., Economides, C., Mayeda, G. S., Burstein, S., & Kloner, R. A. (2009) · International Journal of Impotence Research · doi:10.1038/ijir.2009.59 · Cited by 84
Ose, L., Budinski, D., Hounslow, N. J., & Arneson, V. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903290886 · Cited by 84
A constellation of complications:The metabolic syndrome
Grundy, S. M. (2005) · Clinical cornerstone · doi:10.1016/s1098-3597(05)80066-3 · Cited by 84
Self-citationTremblay, A. J., Lamarche, B., Cohn, J. S., Hogue, J., & Couture, P. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000216750.09611.ec · Cited by 85
Search for an Optimal Atherogenic Lipid Risk Profile: From the Framingham Study
Nam, B., Kannel, W. B., & D’Agostino, R. B. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.055 · Cited by 84
The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus
Elam, M. B., Lovato, L., & Ginsberg, H. N. (2011) · Clinical Lipidology · doi:10.2217/clp.10.84 · Cited by 88
Obesidad, síndrome metabólico y diabetes: implicaciones cardiovasculares y actuación terapéutica
Ezquerra, E. A., Castellano, J. M., & Barrero, A. A. (2008) · Revista Española de Cardiología · doi:10.1157/13123996 · Cited by 95
Ciccacci, C., Fusco, D. D., Cacciotti, L., Morganti, R., D’Amato, C., Novelli, G., Sangiuolo, F. C., Spallone, V., & Borgiani, P. (2012) · Acta Diabetologica · doi:10.1007/s00592-012-0418-x · Cited by 85
Nash, M. S., & Mendez, A. J. (2007) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2007.02.031 · Cited by 84
Johnson, K. M., Dowe, D. A., & Brink, J. A. (2008) · American Journal of Roentgenology · doi:10.2214/ajr.08.1056 · Cited by 84
Illicit use of androgens and other hormones
Kanayama, G., & Pope, H. G. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283524008 · Cited by 84
Aiello, F. A., Khan, A. A., Meltzer, A. J., Gallagher, K. A., McKinsey, J. F., & Schneider, D. B. (2011) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.08.044 · Cited by 83
The 'forgotten' bile acid sequestrants: is now a good time to remember?
Bays, H. E., & Goldberg, R. B. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31815a69fc · Cited by 83
Nakamura, T., Obata, J.-E., Hirano, M., Kitta, Y., Fujioka, D., Saito, Y., Kawabata, K.-I., Watanabe, K., Watanabe, Y., Mishina, H., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.040 · Cited by 83
Nozue, T., Yamamoto, S., Tohyama, S., Umezawa, S., Kunishima, T., Sato, A., Miyake, S., Takeyama, Y., Morino, Y., Yamauchi, T., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.11.004 · Cited by 84
Sezaki, H., Suzuki, F., Akuta, N., Yatsuji, H., Hosaka, T., Kobayashi, M., Suzuki, Y., Arase, Y., Ikeda, K., Miyakawa, Y., et al. (2009) · Intervirology · doi:10.1159/000213504 · Cited by 82
Huang, J., Lu, Y., Cheng, F., Lee, J. N.-Y., & Tsai, L. (2012) · Nutrition Journal · doi:10.1186/1475-2891-11-41 · Cited by 84
Ahmed, H. M., Miller, M. J., Nasir, K., McEvoy, J. W., Herrington, D. M., Blumenthal, R. S., & Blaha, M. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv305 · Cited by 83
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
Rosenblit, P. D. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1178-6 · Cited by 120
Efficacy and safety of rosuvastatin in treatment of dyslipidemia
McKenney, J. M. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.10.1033 · Cited by 86
Remick, J. S., WEINTRAUB, H. S., Setton, R. A., Offenbacher, J., Fisher, E. A. A., & Schwartzbard, A. Z. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e31816b43d3 · Cited by 83
Fibrates in Combination With Statins in the Management of Dyslipidemia
Jacobson, T. A., & Zimmerman, F. H. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.05278.x · Cited by 82
Conard, S. E., Bays, H. E., Leiter, L. A., Bird, S. R., Rubino, J., Lowe, R. S., Tomassini, J. E., & Tershakovec, A. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.075 · Cited by 83
Statin Use and Clinical Osteoarthritis in the General Population: A Longitudinal Study
Kadam, U. T., Blagojevic, M., & Belcher, J. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2382-8 · Cited by 86
Willens, D. E., Cripps, R., Wilson, A. E., Wolff, K., & Rothman, R. L. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.2.60 · Cited by 88
Comparison of Two Point-of-Care Lipid Analyzers for Use in Global Cardiovascular Risk Assessments
Dale, R. A., Jensen, L. H., & Krantz, M. J. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k688 · Cited by 84
Rahman, M., Baimbridge, C., Davis, B. R., Barzilay, J. I., Basile, J., Henriquez, M. A., Huml, A. M., Kopyt, N. P., Louis, G. T., Pressel, S., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.05.027 · Cited by 83
Straka, R. J., Liu, L. Z., Girase, P. S., DeLorenzo, A., & Chapman, R. H. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-53 · Cited by 67
Use of Fibrates in the United States and Canada
Jackevicius, C. A. (2011) · JAMA · doi:10.1001/jama.2011.353 · Cited by 82
Ashtary‐Larky, D., Kelishadi, M. R., Bagheri, R., Moosavian, S. P., Wong, A., Davoodi, S. H., Khalili, P., Dutheil, F., Suzuki, K., & Asbaghi, O. (2021) · Antioxidants · doi:10.3390/antiox10071015 · Cited by 87
The laboratory test utilization management toolbox
Baird, G. S. (2014) · Biochemia Medica · doi:10.11613/bm.2014.025 · Cited by 84
Consensus statement on management of dyslipidemia in Indian subjects
Chandra, K. S., Bansal, M., Nair, T., Iyengar, S. S., Gupta, R., Manchanda, S. C., Mohanan, P. P., Rao, V. D., Manjunath, C. N., Sawhney, J. P. S., et al. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.001 · Cited by 86
Obesity is Related to Increased Menopausal Symptoms among Spanish Women
Fernández‐Alonso, A. M., Cuadros, J. L., Chedraui, P. A., Mendoza, M., Cuadros, Á. M., & Pérez-López, F. R. (2010) · Menopause international · doi:10.1258/mi.2010.010029 · Cited by 82
Designing a patient-centered personal health record to promote preventive care
Krist, A. H., Peele, E., Woolf, S. H., Rothemich, S. F., Loomis, J. F., Longo, D. R., & Kuzel, A. J. (2011) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-11-73 · Cited by 86
Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management
Griffith, M. L., Savani, B. N., & Boord, J. B. (2010) · Blood · doi:10.1182/blood-2010-03-276576 · Cited by 82
Ghadri, J. R., Pazhenkottil, A. P., Nkoulou, R. N., Goetti, R. P., Buechel, R. R., Husmann, L., Herzog, B. A., Wolfrum, M., Wyss, C. A., Templin, C., et al. (2011) · Heart · doi:10.1136/hrt.2010.217281 · Cited by 82
Use of Carotid Intima-Media Thickness and Vascular Age to Modify Cardiovascular Risk Prediction
Gepner, A. D., Keevil, J. G., Wyman, R. A., Korcarz, C. E., Aeschlimann, S. E., Busse, K. L., & Stein, J. H. (2006) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2006.04.009 · Cited by 81
Progress and perspectives in plant sterol and plant stanol research
Jones, P. J. H., Shamloo, M., MacKay, D., Rideout, T. C., Myrie, S. B., Plat, J., Roullet, J., Baer, D. J., Calkins, K. L., Davis, H. R., et al. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy032 · Cited by 86
A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
Ling (2013) · Cardiology Research · doi:10.4021/cr270w · Cited by 85
Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy
Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.002 · Cited by 81
Zhang, J., Fu, L., Shi, J., Chen, X., Li, Y., Ma, B., & Zhang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078151 · Cited by 81
National Lipid Association Annual Summary of Clinical Lipidology 2015
Bays, H. E., Jones, P. H., Brown, W. V., & Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.10.002 · Cited by 82
Fentoğlu, Ö., Kırzıoğlu, F. Y., Özdem, M., Koçak, H., Sütçü, R., & Sert, T. (2011) · Oral Diseases · doi:10.1111/j.1601-0825.2011.01880.x · Cited by 81
Coronary Artery Calcium Improves Risk Classification in Younger Populations
Paixao, A. R. M., Ayers, C. R., Sabbagh, A. E., Sanghavi, M., Berry, J. D., Rohatgi, A. K., Kumbhani, D. J., McGuire, D. K., Das, S. R., de Lemos, J. A., et al. (2015) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2015.06.015 · Cited by 83
Optimal Medical Management of Peripheral Arterial Disease
Rice, T., & Lumsden, A. (2006) · Vascular and Endovascular Surgery · doi:10.1177/1538574406291835 · Cited by 88
Reducing Cardiovascular Complications of Type 2 Diabetes by Targeting Multiple Risk Factors
Reasner, C. A. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31817ffe5a · Cited by 82
van Kempen, B. J. H., Spronk, S., Koller, M., Elias‐Smale, S. E., Fleischmann, K. E., Ikram, M. A., Krestin, G. P., Albert Hofman, D., Witteman, J. C. M., & Hunink, M. G. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.056 · Cited by 81
Yang, X., So, W. Y., Ko, G. T. C., Ronald, C. W., Kong, A. P. S., Chow, C. C., Tong, P. C. Y., & Chan, J. C. N. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071474 · Cited by 81
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance
Davidson, M. H. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.6.547 · Cited by 80
WEINTRAUB, H. S. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.041 · Cited by 82
Vitamin D deficiency, myositis–myalgia, and reversible statin intolerance
Glueck, C. J., Budhani, S., Masineni, S. S., Abuchaibe, C., Khan, N., Wang, P., & Goldenberg, N. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.598144 · Cited by 81
Paramsothy, P., Knopp, R. H., Bertoni, A. G., Blumenthal, R. S., Wasserman, B. A., Tsai, M. Y., Rue, T. C., Wong, N. D., & Heckbert, S. R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.073 · Cited by 80
Leblanc, V., Bégin, C., Hudon, A.-M., Royer, M., Corneau, L., Dodin, S., & Lemieux, S. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-107 · Cited by 84
Lipid Management in Type 2 Diabetes
Solano, M. P., & Goldberg, R. B. (2006) · Clinical Diabetes · doi:10.2337/diaclin.24.1.27 · Cited by 82
Yao, F., Huang, Y., Zhang, Y., Dong, Y., Ma, H., Deng, C., Lin, H., Liu, D., & Lu, K. (2012) · International Journal of Andrology · doi:10.1111/j.1365-2605.2012.01273.x · Cited by 80
Boer, H., Proost, J. H., Nuver, J., Bunskoek, S., Gietema, J., Geubels, B. M., Altena, R., Zwart, N. R. K., Oosting, S. F., Vonk, J. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv369 · Cited by 80
Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 86
Zibaeenezhad, M., Farhadi, P., Attar, A., Mosleh, A., Amirmoezi, F., & Azimi, A. (2017) · Nutrition & Diabetes · doi:10.1038/nutd.2017.8 · Cited by 82
Foody, J. M., Rathore, S. S., Galusha, D. H., Masoudi, F. A., Havranek, E. P., Radford, M. J., & Krumholz, H. M. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.00635.x · Cited by 80
Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-9-200911030-00144 · Cited by 79
Metadata
- Authors
- Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J.
- Affiliations
- American College of Cardiology (US)
- Venue
- Circulation
- Published
- 2004-07-13
- Volume
- 110
- Issue
- 2
- Pages
- 227-239
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2106343349
- Cited by
- 6,902
- References
- 54
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 72 · 2023: 71 · 2022: 85 · 2021: 100 · 2020: 127 · 2019: 137 · 2018: 152 · 2017: 189 · 2016: 248 · 2015: 324 · 2014: 382 · 2013: 506 · 2012: 489
- FWCI
- 539.21
- Type
- journal article
- Language
- en
- Update notices
- correction (2004-08-10)
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Heart Association
- American College of Cardiology Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- Adult Treatment Panel III, LDL cholesterol targets, statin therapy, cholesterol-lowering therapy, diabetes mellitus, older adults, triglycerides, HDL cholesterol, nicotinic acid, therapeutic lifestyle changes, cardiovascular risk stratification, hypercholesterolemia, metabolic syndrome, cardiovascular disease prevention
- MeSH terms
- Aged, Anticholesteremic Agents, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Humans, Hypercholesterolemia, Hypertension, Cholesterol, LDL, Middle Aged, Myocardial Infarction, Patient Education as Topic, Risk, Risk Factors, Comorbidity, Thrombolytic Therapy, Randomized Controlled Trials as Topic, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
